周围T淋巴细胞的免疫特征决定了在不可切除的肝细胞癌中对跨动脉化学栓塞的反应
Lei Peng1, Qi Liang1, Peng Fei Rong1,2,3
1Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Therapeutic advances in gastroenterology
|May 9, 2025
概括
这项研究发现,周围血液中特定的T淋巴细胞亚群可以预测通过导管动脉化学栓塞 (TACE) 对不可切除的肝细胞癌 (uHCC) 的有效性. 识别这些生物标志物有助于个性化治疗,以获得更好的患者结果.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物标志物发现发现
背景情况:
- 过导管动脉化学栓塞 (TACE) 是对不可切除的肝细胞癌 (uHCC) 的一线治疗方法,但它的有效性各不相同.
- 确定可靠的生物标志物来预测TACE反应对于临床决策至关重要.
研究的目的:
- 研究与TACE折射性相关的外周血液中的T淋巴细胞亚群和通路.
- 开发对HHCC患者TACE疗效的预测方法.
主要方法:
- 对50名接受TACE的hhCC患者进行观察性研究.
- 使用流细胞计和RNA测序对外围血液T淋巴细胞的分析.
- 评估TACE反应和与免疫细胞概况和基因表达的相关性.
主要成果:
- 48%的患者表现为TACE失败 (无反应).
- 非响应组增加了衰老的T细胞 (衰老) 和减少了记忆干T细胞 (SCM).
- CD8+ TSCM和CD8+ T衰老亚群是TACE疗效的显著预测因素.
结论:
- 在TACE响应者和非响应者之间存在外围T淋巴细胞概况的显著差异.
- CD8+ TSCM和CD8+ T衰老子集显示出预测TACE疗效和生存的生物标志物的潜力.
- 这些发现可以为HHCC患者提供个性化的治疗策略.
更多相关视频
07:32Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
Published on: April 12, 2024
08:25Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
相关概念视频
01:40Cell-mediated Immune Responses
65.5K
Overview
65.5K
01:27Tumor Immunotherapy
401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401